Analysts expect over 2021 decreasing revenue arGEN-X

Tomorrow the Belgian arGEN-X will publish its past quarters figures. For this year arGEN-X 's revenue will be around 63.6 million euros. This is according to the average of the analysts' estimates. This is slightly lower than 2020's revenue of 69.78 million euros.

Historical revenues and results arGEN-X plus estimates 2020

financiële analyse

The analysts expect for 2021 a net loss of 453 million euros. The majority of the analysts expects for this year a loss per share of 10.06 euros. So the price/earnings-ratio equals -27.36.

For this year analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies equals a moderate 0.37 percent.

Most recent target prices around 285 euros

The most recent recommendations for the biotech company are from Barclays , JP Morgan and KBC Securities.

arGEN-X 's market capitalization is based on the number of outstanding shares around 9.9 billion euros. The arGEN-X stock was the past 12 months quite volatile. Since last March the stock is even 107 percent higher. This year the stock price moved between 93 and 315 euro.

Historical stock prices arGEN-X

historical stocks argen-x

Click here for dividend arGEN-X. At 13.49 the stock trades 1.16 percent lower at 275.2 euros.

Analist.nl Nieuwsdienst: +31 084-0032-842
nieuws@analist.nl

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.